Thermo Fisher Scientific Inc. (TMO) AI Stock Analysis

Thermo Fisher Scientific Inc. is a global provider of solutions for life sciences, analytical instruments, specialty diagnostics, and laboratory products and services. The Life Sciences Solutions segment supplies reagents, instruments, and consumables used in biological and medical research, drug discovery, and disease diagnosis. The Analytical Instruments segment offers instruments, software, and consumables for laboratories, production lines, and field settings across academic, government, and industrial applications. Specialty Diagnostics provides immunodiagnostic reagent kits and tests for allergy, autoimmunity, and microbiology. The Laboratory Products and Services segment offers freezers, safety cabinets, water analysis tools, and laboratory consumables.

Thermo Fisher grew annual revenue from $39.21B in FY2021 to $44.56B in FY2025, reflecting a 5-year compound annual growth rate of 6.7%. Revenue rose 3.9% in FY2025 following a flat FY2024 of $42.88B and a 4.6% decline in FY2023. Gross margin stood at 40.9% in FY2025, down from 50.1% in FY2021, while operating margin was 18.2% compared to 26.3% in FY2021. Annual net income reached $6.74B in FY2025 with diluted earnings per share of $22.87. For the trailing twelve months ended June 30, 2026, revenue was $46.34B, supported by quarterly revenue growth of 10.5% and quarterly earnings growth of 9.4%.

As of June 30, 2026, Thermo Fisher held $4.06B in cash and short-term investments against total debt of $42.55B, resulting in net debt of $38.48B. Total assets were $113.17B and shareholders' equity was $52.68B, yielding a debt-to-equity ratio of 0.81 and a current ratio of 1.55. In FY2025, operating cash flow was $7.82B and free cash flow reached $6.29B. The company deployed cash toward $1.52B in capital expenditures, $3.00B in share buybacks, and $636.0M in dividends paid.

Thermo Fisher trades at a trailing price-to-earnings multiple of 37.1x and a forward P/E of 24.2x, which compare to 27.2x and 16.5x for the median of its S&P 500 Healthcare peers. Its enterprise value to EBITDA ratio is 23.6x, above the peer group median of 15.0x, while its price-to-sales ratio is 5.5x against the peer median of 3.4x. Over the past year, the stock returned 29.0%, outpacing the S&P 500 return of 16.8%. However, its five-year return of 20.2% trails the index return of 83.0%.

Thermo Fisher pays a quarterly dividend with an annualized forward payout of $1.88 per share, representing a dividend yield of 0.27%. The company maintains a payout ratio of 7.7% and has paid dividends for 15 consecutive years. Over the past five years, dividend growth annualized at 14.3%. The most recent ex-dividend date was September 15, 2026.

Wall Street coverage includes 20 Strong Buy, 4 Buy, 3 Hold, and 1 Sell ratings. The mean price target is $690.62, representing a 0.1% difference from the last close of $690.00. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $47.89B and EPS of $25.15. Thermo Fisher has beaten earnings estimates in each of the last 4 quarters, and the next earnings date is October 21, 2026.

This page is an AI-written research summary of Thermo Fisher Scientific Inc. (TMO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TMO income statement, TMO balance sheet, TMO key metrics, TMO analyst forecast, TMO chart. See the TMO stock overview for the latest quote and news.